EP3072519A4 - Peptide having angiogenesis inhibitory activity and composition containing same - Google Patents
Peptide having angiogenesis inhibitory activity and composition containing same Download PDFInfo
- Publication number
- EP3072519A4 EP3072519A4 EP14864515.3A EP14864515A EP3072519A4 EP 3072519 A4 EP3072519 A4 EP 3072519A4 EP 14864515 A EP14864515 A EP 14864515A EP 3072519 A4 EP3072519 A4 EP 3072519A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- peptide
- composition containing
- inhibitory activity
- containing same
- angiogenesis inhibitory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
- C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20130142897 | 2013-11-22 | ||
| KR20140020605 | 2014-02-21 | ||
| PCT/KR2014/011280 WO2015076621A1 (en) | 2013-11-22 | 2014-11-21 | Peptide having angiogenesis inhibitory activity and composition containing same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| EP3072519A1 EP3072519A1 (en) | 2016-09-28 |
| EP3072519A4 true EP3072519A4 (en) | 2017-04-19 |
| EP3072519B1 EP3072519B1 (en) | 2020-08-19 |
Family
ID=53179816
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP14864515.3A Active EP3072519B1 (en) | 2013-11-22 | 2014-11-21 | Peptide having angiogenesis inhibitory activity and composition containing same |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10034922B2 (en) |
| EP (1) | EP3072519B1 (en) |
| JP (1) | JP6553605B2 (en) |
| KR (3) | KR102494803B1 (en) |
| CN (1) | CN105848667B (en) |
| ES (1) | ES2818921T3 (en) |
| WO (1) | WO2015076621A1 (en) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102578891B1 (en) | 2012-05-11 | 2023-09-15 | 주식회사 젬백스앤카엘 | Anti-inflammatory Peptides and Composition comprising the same |
| EP2875826B1 (en) | 2012-05-11 | 2017-08-23 | KAEL-GemVax Co.,Ltd | Composition for preventing or treating sepsis |
| ES2981865T3 (en) | 2012-07-11 | 2024-10-10 | Gemvax & Kael Co Ltd | Conjugate comprising a cell-penetrating peptide and compositions comprising the same |
| WO2014171792A1 (en) | 2013-04-19 | 2014-10-23 | 주식회사 카엘젬백스 | Composition for treating and preventing ischemic damage |
| CN105535931A (en) | 2013-06-07 | 2016-05-04 | 凯尔杰姆维克斯有限公司 | Biological markers useful in cancer immunotherapy |
| TWI539960B (en) | 2013-06-21 | 2016-07-01 | 凱爾傑姆維克斯有限公司 | Hormone secretion modulator, composition comprising the same, and use of the same |
| ES2809251T3 (en) | 2013-12-17 | 2021-03-03 | Gemvax & Kael Co Ltd | Composition to treat prostate cancer |
| US10632349B2 (en) | 2017-11-03 | 2020-04-28 | Parsons Xtreme Golf, LLC | Golf club heads and methods to manufacture golf club heads |
| EP3130345B9 (en) | 2014-04-11 | 2022-05-04 | Gemvax & Kael Co., Ltd. | Peptide having fibrosis inhibitory activity and composition containing same |
| ES2962532T3 (en) | 2014-04-30 | 2024-03-19 | Gemvax & Kael Co Ltd | Composition for organ, tissue or cell transplantation, transplant kit and procedure |
| KR102413243B1 (en) | 2014-12-23 | 2022-06-27 | 주식회사 젬백스앤카엘 | Peptides for treating ophthalmopathy and the Composition Comprising the Same |
| EP3263122B1 (en) | 2015-02-27 | 2020-05-06 | Gemvax & Kael Co., Ltd. | Peptide for preventing hearing loss, and composition comprising same |
| WO2017003267A1 (en) | 2015-07-02 | 2017-01-05 | 주식회사 젬백스앤카엘 | Peptide having anti-viral effect and composition containing same |
| WO2017176087A1 (en) | 2016-04-07 | 2017-10-12 | 주식회사 젬백스앤카엘 | Peptide having effects of increasing telomerase activity and extending telomere, and composition containing same |
| KR102612117B1 (en) * | 2017-01-13 | 2023-12-12 | 바소뮨 테라퓨틱스 인코포레이티드 | Substances that promote angiogenesis and methods and uses thereof |
| CN108421050A (en) * | 2017-02-15 | 2018-08-21 | 闵晓洁 | MicroRNA interferes reverse transcriptase of telomere plasmid to inhibit retina, choroidal neovascularization novel formulation |
| KR101998155B1 (en) * | 2017-09-22 | 2019-07-10 | (주)케어젠 | Peptides for inhibiting angiogenesis and the use thereof |
| WO2020053773A1 (en) * | 2018-09-11 | 2020-03-19 | Anbition S.R.L. | Peptides and medical uses thereof |
| MA54325A (en) | 2019-06-05 | 2022-05-11 | Regeneron Pharma | DEVICES AND METHODS FOR ACCURATE DOSE DELIVERY |
| KR102467670B1 (en) * | 2022-05-16 | 2022-11-17 | 줄리아 연구소 주식회사 | Pharmaceutical composition and health functional food for preventing or treating angiogenesis disease comprising shc1 protein or anti-shc1 antibody |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
| KR102587729B1 (en) * | 2023-02-27 | 2023-10-12 | 주식회사 아이바이오코리아 | Composition for treating diabetic retinopathy comprising peptides |
| WO2024237768A1 (en) * | 2023-05-17 | 2024-11-21 | 주식회사 젬백스앤카엘 | Composition comprising gv1001 for preventing or treating macular degeneration |
| KR20250162964A (en) | 2024-05-09 | 2025-11-20 | 국립해양생물자원관 | Compositions for inhibiting angiogenesis comprising novel peptide |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013167299A1 (en) * | 2012-05-11 | 2013-11-14 | Kael-Gemvax Co., Ltd. | Anti-inflammatory peptides and composition comprising the same |
| WO2015182837A1 (en) * | 2014-05-28 | 2015-12-03 | 주식회사 젬백스앤카엘 | Composition for inhibiting myeloid-derived suppressor cells |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR930001915B1 (en) | 1990-06-27 | 1993-03-20 | 포항종합제철 주식회사 | Low temperature sintered piezoelectric ceramic material manufacturing method |
| EP0930876B2 (en) | 1996-07-22 | 2010-07-07 | Renovo Limited | Use of compounds that promote oestrogenic activity for acclerating the healing of skin wounds |
| US6610839B1 (en) * | 1997-08-14 | 2003-08-26 | Geron Corporation | Promoter for telomerase reverse transcriptase |
| TR199902800T2 (en) | 1997-05-15 | 2000-04-21 | Chugai Seiyaku Kabushiki Kaisha | A substance that treats cacaxia. |
| CN1270634A (en) | 1997-07-01 | 2000-10-18 | 卡姆比亚生物系统有限责任公司 | Vertebrate telomerase genes and proteins and uses thereof |
| US7030211B1 (en) | 1998-07-08 | 2006-04-18 | Gemvax As | Antigenic peptides derived from telomerase |
| US6378526B1 (en) | 1998-08-03 | 2002-04-30 | Insite Vision, Incorporated | Methods of ophthalmic administration |
| IL132406A0 (en) | 1998-10-21 | 2001-03-19 | Pfizer Prod Inc | Treatment of bph with cgmp elevators |
| US6815426B2 (en) * | 2001-02-16 | 2004-11-09 | E. I. Du Pont De Nemours And Company | Angiogenesis-inhibitory tripeptides, compositions and their methods of use |
| WO2002066512A1 (en) * | 2001-02-16 | 2002-08-29 | E.I. Dupont De Nemours And Company | Angiogenesis-inhibitory tripeptides, compositions and their methods of use |
| CA2443636C (en) | 2001-04-10 | 2009-11-17 | Nippon Shinyaku Co., Ltd. | Remedial agent for chronic articular rheumatism |
| CN100556450C (en) | 2001-05-16 | 2009-11-04 | 耶达研究发展有限公司 | Application of IL-18 inhibitor in treatment or prevention of sepsis |
| AU2002363231A1 (en) | 2001-10-29 | 2003-05-12 | Baylor College Of Medicine | Human telomerase reverse transcriptase as a class-ii restricted tumor-associated antigen |
| US7786084B2 (en) | 2001-12-21 | 2010-08-31 | Biotempt B.V. | Treatment of burns |
| AU2003240754B2 (en) | 2002-04-10 | 2009-02-26 | Merck Serono Sa | Use of osteoprotegerin for the prevention and/or treatment of fibrosis/sclerosis |
| KR20050020987A (en) | 2002-06-12 | 2005-03-04 | 바이오겐 아이덱 엠에이 인코포레이티드 | Method of treating ischemia reperfusion injury using adenosine receptor antagonists |
| CN1812805A (en) | 2003-06-25 | 2006-08-02 | 坎巴斯有限公司 | Peptides and peptidomimetics having immune-modulating, anti-inflammatory, and anti-viral activity |
| KR20050040517A (en) | 2003-10-29 | 2005-05-03 | 주식회사 오리엔트 | Transgenic mouse possessing resistance for ischemia |
| ES2258694T3 (en) | 2003-11-11 | 2006-09-01 | Mattern, Udo | ADMINISTRATION SYSTEM FOR CONTROLLED RELEASE OF SEX HORMONES FOR NASAL APPLICATIONS. |
| GB0426146D0 (en) | 2004-11-29 | 2004-12-29 | Bioxell Spa | Therapeutic peptides and method |
| EP1990049A3 (en) | 2005-03-21 | 2008-11-26 | Vicus Therapeutics SPE 1, LLC | Combination therapy of beta-blockers and non-steroidal anti-inflammatory drugs (NSAID) |
| WO2007061029A1 (en) | 2005-11-25 | 2007-05-31 | Keio University | Therapeutic agent for prostate cancer |
| WO2007069068A2 (en) | 2005-12-16 | 2007-06-21 | Diatos | Cell penetrating peptide conjugates for delivering nucleic acids into cells |
| WO2007097561A1 (en) | 2006-02-20 | 2007-08-30 | Ewha University - Industry Collaboration Foundation | Peptide having cell membrane penetrating activity |
| EP2044108A4 (en) | 2006-07-24 | 2010-06-30 | Forhumantech Co Ltd | Pharmaceutical composition for alleviation and treatment of ischemic conditions and method for delivering the same |
| ATE534661T1 (en) * | 2006-10-12 | 2011-12-15 | Angeletti P Ist Richerche Bio | FUSION PROTEIN FROM TELOMERASE AND REVERSE TRANSCRIPTASE, NUCLEOTIDES CODING THEREFOR AND APPLICATIONS THEREOF |
| AU2008211854C1 (en) | 2007-01-29 | 2014-01-23 | Procell Therapeutics Inc. | Novel macromolecule transduction domains and methods for identification and uses thereof |
| CN101855553B (en) | 2007-06-29 | 2014-06-11 | 韩国安国药品株式会社 | Predictive markers for ovarian cancer |
| MX2010001684A (en) | 2007-08-15 | 2010-04-21 | Amunix Inc | Compositions and methods for modifying properties of biologically active polypeptides. |
| CL2008002782A1 (en) * | 2007-09-21 | 2009-07-31 | Genentech Inc | Neutralizing anti-bv8 antibody; composition comprising it; and its use to treat tumors in humans previously treated with a vascular endothelial growth factor antagonist. |
| WO2009054996A2 (en) | 2007-10-25 | 2009-04-30 | Genelux Corporation | Systems and methods for viral therapy |
| GB2455539B (en) | 2007-12-12 | 2012-01-18 | Cambridge Entpr Ltd | Anti-inflammatory compositions and combinations |
| DK2310044T3 (en) | 2008-06-16 | 2016-12-12 | Mediolanum Farm S P A | Antitumor IMMUNOTHERAPY |
| ES2334315B1 (en) | 2008-07-29 | 2011-02-28 | Universitat Pompeu Fabra | PEPTIDES WITH CAPACITY OF CELL PENETRATION AND ITS USES. |
| WO2010032322A1 (en) | 2008-09-22 | 2010-03-25 | 日清ファルマ株式会社 | Antiinflammatory peptide |
| KR101169030B1 (en) | 2009-01-21 | 2012-07-26 | 애니젠 주식회사 | Novel Cell Penetrating Domain and Intracellular Delivery System Comprising the Same |
| EP2251028A1 (en) | 2009-05-12 | 2010-11-17 | Biocompatibles Uk Ltd. | Treatment of eye diseases using encapsulated cells encoding and secreting an anti-angiogenic factor and/or a neuroprotective factor |
| US7928067B2 (en) | 2009-05-14 | 2011-04-19 | Ischemix Llc | Compositions and methods for treating ischemia and ischemia-reperfusion injury |
| WO2010134537A1 (en) | 2009-05-20 | 2010-11-25 | 東レ株式会社 | Cell membrane-permeable peptides |
| KR20110057049A (en) | 2009-11-23 | 2011-05-31 | 박의신 | Functional Prostatitis Therapeutics |
| KR20110062943A (en) | 2009-12-04 | 2011-06-10 | 주식회사종근당 | Prostate hypertrophy prevention or treatment using quinazoline derivative as an active ingredient |
| US9200277B2 (en) | 2010-01-11 | 2015-12-01 | Curna, Inc. | Treatment of sex hormone binding globulin (SHBG) related diseases by inhibition of natural antisense transcript to SHBG |
| EP3581649A1 (en) * | 2010-02-16 | 2019-12-18 | Ultimovacs ASA | Polypeptides |
| KR101335203B1 (en) * | 2010-03-26 | 2013-11-29 | 숙명여자대학교산학협력단 | Peptides for Promotion of Angiogenesis and the use thereof |
| FR2960542B1 (en) | 2010-05-27 | 2012-08-17 | Esther Suzy Arlette Fellous | PEPTIDE AS A DRUG, ESPECIALLY FOR THE TREATMENT OF CANCER |
| KR101263212B1 (en) | 2010-05-28 | 2013-05-10 | 성신여자대학교 산학협력단 | A new cell-permeable peptide and its use |
| WO2011150494A1 (en) | 2010-05-30 | 2011-12-08 | The Governing Council Of The University Of Toronto | Mitochondrial penetrating peptides as carriers for anticancer compounds |
| KR101388372B1 (en) | 2010-06-11 | 2014-04-23 | 한국화학연구원 | Novel compound having hearing protection effects |
| KR101348284B1 (en) | 2010-09-09 | 2014-01-03 | 주식회사 나이벡 | Combination of Human derived Cell Permeable Peptide and Bioactive Peptide (TOPscovery) and Use Thereof |
| US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
| KR20120121196A (en) | 2011-04-26 | 2012-11-05 | 주식회사 글루칸 | Treatment agent for osteoarthritis |
| KR101284772B1 (en) | 2011-05-24 | 2013-07-17 | 정종문 | Functional food composition with the effects of anti-inflammation and pain-relieving |
| KR20120133661A (en) | 2011-05-31 | 2012-12-11 | 주식회사 바이오포트코리아 | Anti-inflammatory agent containing astaxanthin |
| KR101288053B1 (en) | 2011-07-04 | 2013-07-23 | 동국대학교 산학협력단 | Composition for Prevention or Treatment of inner ear damage Comprising an extract of Piper longum L. |
| KR101361445B1 (en) | 2011-12-26 | 2014-02-12 | 성균관대학교산학협력단 | Composition comprising peptide, 5-fluorouracil, and mature dendritic cells for cancer treatment |
| JP5577472B2 (en) | 2012-02-10 | 2014-08-20 | 医療法人社団博心厚生会 | Monocyte proliferating agent, monocyte growth medium, monocyte production method, dendritic cell production method, and dendritic cell vaccine production method |
| WO2013135266A1 (en) | 2012-03-12 | 2013-09-19 | Gemvax As | Treatment of non-small cell lung carcinoma by active immunotherapy |
| EP2875826B1 (en) | 2012-05-11 | 2017-08-23 | KAEL-GemVax Co.,Ltd | Composition for preventing or treating sepsis |
| ES2981865T3 (en) | 2012-07-11 | 2024-10-10 | Gemvax & Kael Co Ltd | Conjugate comprising a cell-penetrating peptide and compositions comprising the same |
| US20150125438A1 (en) | 2012-07-20 | 2015-05-07 | Sang Jae Kim | Anti-Inflammatory Peptides and Composition Comprising the Same |
| WO2014046481A1 (en) | 2012-09-19 | 2014-03-27 | 주식회사 카엘젬백스 | Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate |
| TWI655204B (en) | 2012-09-19 | 2019-04-01 | 韓商傑姆維克斯＆凱爾有限公司 | Transmembrane peptide and conjugates and compositions comprising the same (3) |
| KR102038487B1 (en) | 2012-09-19 | 2019-10-30 | 주식회사 젬백스앤카엘 | Antimicrobial or antifungal composition comprising telomerase peptide |
| KR102201429B1 (en) | 2012-09-19 | 2021-01-12 | 주식회사 젬백스앤카엘 | Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate |
| WO2014171792A1 (en) | 2013-04-19 | 2014-10-23 | 주식회사 카엘젬백스 | Composition for treating and preventing ischemic damage |
| CN105535931A (en) | 2013-06-07 | 2016-05-04 | 凯尔杰姆维克斯有限公司 | Biological markers useful in cancer immunotherapy |
| TWI539960B (en) | 2013-06-21 | 2016-07-01 | 凱爾傑姆維克斯有限公司 | Hormone secretion modulator, composition comprising the same, and use of the same |
| CN105899224B (en) | 2013-10-23 | 2019-12-13 | 珍白斯凯尔有限公司 | Composition for treating and preventing benign prostatic hyperplasia |
| ES2809251T3 (en) | 2013-12-17 | 2021-03-03 | Gemvax & Kael Co Ltd | Composition to treat prostate cancer |
| EP3130345B9 (en) | 2014-04-11 | 2022-05-04 | Gemvax & Kael Co., Ltd. | Peptide having fibrosis inhibitory activity and composition containing same |
| ES2962532T3 (en) | 2014-04-30 | 2024-03-19 | Gemvax & Kael Co Ltd | Composition for organ, tissue or cell transplantation, transplant kit and procedure |
| KR102413243B1 (en) | 2014-12-23 | 2022-06-27 | 주식회사 젬백스앤카엘 | Peptides for treating ophthalmopathy and the Composition Comprising the Same |
| EP3263122B1 (en) | 2015-02-27 | 2020-05-06 | Gemvax & Kael Co., Ltd. | Peptide for preventing hearing loss, and composition comprising same |
| KR20170054310A (en) | 2015-11-09 | 2017-05-17 | 주식회사 젬백스앤카엘 | Dendritic Cell Therapeutic Agent and Immunotherapeutic Agent Comprising a Peptide Derived from Telomerase, and Method for Treatment Using the Same |
-
2014
- 2014-11-21 KR KR1020227003326A patent/KR102494803B1/en active Active
- 2014-11-21 JP JP2016533182A patent/JP6553605B2/en active Active
- 2014-11-21 US US15/038,269 patent/US10034922B2/en active Active
- 2014-11-21 EP EP14864515.3A patent/EP3072519B1/en active Active
- 2014-11-21 CN CN201480070167.3A patent/CN105848667B/en active Active
- 2014-11-21 WO PCT/KR2014/011280 patent/WO2015076621A1/en not_active Ceased
- 2014-11-21 KR KR1020237003083A patent/KR102694658B1/en active Active
- 2014-11-21 ES ES14864515T patent/ES2818921T3/en active Active
- 2014-11-21 KR KR1020167015069A patent/KR102359396B1/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013167299A1 (en) * | 2012-05-11 | 2013-11-14 | Kael-Gemvax Co., Ltd. | Anti-inflammatory peptides and composition comprising the same |
| WO2015182837A1 (en) * | 2014-05-28 | 2015-12-03 | 주식회사 젬백스앤카엘 | Composition for inhibiting myeloid-derived suppressor cells |
Non-Patent Citations (3)
| Title |
|---|
| KIM BU-KYUNG ET AL: "Tumor-suppressive effect of a telomerase-derived peptide by inhibiting hypoxia-induced HIF-1[alpha]-VEGF signaling axis.", BIOMATERIALS MAR 2014, vol. 35, no. 9, March 2014 (2014-03-01), pages 2924 - 2933, XP028829049, ISSN: 1878-5905 * |
| RUDEN MARIA ET AL: "Novel anticancer therapeutics targeting telomerase", CANCER TREATMENT REVIEWS, vol. 39, no. 5, 23 August 2013 (2013-08-23), pages 444 - 456, XP028593060, ISSN: 0305-7372, DOI: 10.1016/J.CTRV.2012.06.007 * |
| See also references of WO2015076621A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| KR102694658B1 (en) | 2024-08-14 |
| WO2015076621A1 (en) | 2015-05-28 |
| JP6553605B2 (en) | 2019-07-31 |
| KR102359396B1 (en) | 2022-02-08 |
| US10034922B2 (en) | 2018-07-31 |
| KR20160079881A (en) | 2016-07-06 |
| KR102494803B1 (en) | 2023-02-06 |
| KR20230020009A (en) | 2023-02-09 |
| US20160296604A1 (en) | 2016-10-13 |
| EP3072519B1 (en) | 2020-08-19 |
| KR20220020411A (en) | 2022-02-18 |
| EP3072519A1 (en) | 2016-09-28 |
| CN105848667B (en) | 2020-05-19 |
| JP2016539121A (en) | 2016-12-15 |
| CN105848667A (en) | 2016-08-10 |
| ES2818921T3 (en) | 2021-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3043820A4 (en) | Methods and compositions comprising purified recombinant polypeptides | |
| EP3114217A4 (en) | Caspase polypeptides having modified activity and uses thereof | |
| EP3130345A4 (en) | Peptide having fibrosis inhibitory activity and composition containing same | |
| EP2979537A4 (en) | Combine | |
| EP3060561A4 (en) | Strigolactone formulations and uses thereof | |
| EP3030566A4 (en) | Aza-pyridone compounds and uses thereof | |
| EP3030266A4 (en) | Topical compositions and methods of using the same | |
| EP3035818A4 (en) | Cosmetic systems | |
| EP3052520A4 (en) | Stabilized polypeptides and uses thereof | |
| EP2968418A4 (en) | Preparations derived from placental materials of making and using same | |
| IL243899B (en) | Anti-garp protein and uses thereof | |
| PT3058936T (en) | Peptide composition and uses thereof | |
| CA3284288A1 (en) | Topical compositions and methods of using the same | |
| AU2014310479B2 (en) | Novel adsorbent composition and use thereof | |
| EP3085385A4 (en) | Pharmaceutical composition comprising adalimumab | |
| EP3030072A4 (en) | Insecticidal polypeptides having broad spectrum activity and uses thereof | |
| EP3039131A4 (en) | Enzyme composition and uses thereof | |
| EP3048110A4 (en) | Composition comprising peptide derived from adiponectin | |
| EP2983681A4 (en) | Therapeutic compositions and uses thereof | |
| EP3010990A4 (en) | Adhesive compositions and use thereof | |
| HRP20181705T1 (en) | Antimicrobial peptide and uses thereof | |
| EP3046929A4 (en) | Erk-derived peptides and uses thereof | |
| EP3009497A4 (en) | Cleanser composition | |
| EP3061771A4 (en) | Novel four-ctl epitope-joined peptide | |
| EP3077510A4 (en) | Antisense compounds and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20160622 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| AX | Request for extension of the european patent |
Extension state: BA ME |
|
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: GEMVAX & KAEL CO., LTD. |
|
| DAX | Request for extension of the european patent (deleted) | ||
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20170320 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 35/00 20060101ALI20170314BHEP Ipc: A61K 38/17 20060101ALI20170314BHEP Ipc: A61K 38/10 20060101AFI20170314BHEP |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| 17Q | First examination report despatched |
Effective date: 20171222 |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
| INTG | Intention to grant announced |
Effective date: 20200210 |
|
| GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
| GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
| GRAL | Information related to payment of fee for publishing/printing deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR3 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| GRAR | Information related to intention to grant a patent recorded |
Free format text: ORIGINAL CODE: EPIDOSNIGR71 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
| GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
| INTC | Intention to grant announced (deleted) | ||
| AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| INTG | Intention to grant announced |
Effective date: 20200714 |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602014069275 Country of ref document: DE |
|
| REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1303175 Country of ref document: AT Kind code of ref document: T Effective date: 20200915 |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
| REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
| REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20200819 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201119 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200819 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200819 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200819 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200819 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201221 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201120 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201119 |
|
| REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1303175 Country of ref document: AT Kind code of ref document: T Effective date: 20200819 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200819 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200819 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200819 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200819 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201219 |
|
| REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2818921 Country of ref document: ES Kind code of ref document: T3 Effective date: 20210414 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200819 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200819 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200819 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200819 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200819 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602014069275 Country of ref document: DE |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200819 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200819 |
|
| PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200819 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200819 |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
| 26N | No opposition filed |
Effective date: 20210520 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20201121 |
|
| REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20201130 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200819 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20201130 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20201130 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20201121 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200819 Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200819 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200819 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200819 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20201130 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R081 Ref document number: 602014069275 Country of ref document: DE Owner name: KIM, SANG JAE, SEONGNAM-SI, KR Free format text: FORMER OWNER: GEMVAX & KAEL CO., LTD., DAEJEON, KR Ref country code: DE Ref legal event code: R081 Ref document number: 602014069275 Country of ref document: DE Owner name: GEMVAX & KAEL CO., LTD., KR Free format text: FORMER OWNER: GEMVAX & KAEL CO., LTD., DAEJEON, KR |
|
| REG | Reference to a national code |
Ref country code: GB Ref legal event code: 732E Free format text: REGISTERED BETWEEN 20231123 AND 20231129 |
|
| REG | Reference to a national code |
Ref country code: ES Ref legal event code: PC2A Owner name: SANG JAE KIM Effective date: 20240611 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20250924 Year of fee payment: 12 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20250922 Year of fee payment: 12 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20250925 Year of fee payment: 12 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20250922 Year of fee payment: 12 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20251215 Year of fee payment: 12 |